SEATTLE--(BUSINESS WIRE)--May 24, 2019--
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage
immunotherapy company focused on developing innovative treatments for
cancer, autoimmune/inflammatory, and other diseases, today announced the
company will participate in three upcoming investor conferences in June.
Jefferies 2019 Healthcare Conference
Date: Thursday, June 6, 2019
Time: 2:00 p.m. Eastern Time
Location: New York, NY
Raymond James Life Sciences and MedTech Conference
Date: Wednesday, June 19, 2019
Time: 1:15 p.m. Eastern Time
Location: New York, NY
JMP Securities Life Sciences Conference
Date: Thursday, June 20, 2019
Time: 1:30 p.m. Eastern Time
Location: New York, NY
A live webcast of each presentation will be available online in the
investor relations section of the company’s website at https://ir.alpineimmunesciences.com/events.
A replay of the presentations will be available on the company website
for 90 days following the webcast.
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is committed to leading a new wave of
functional immune therapeutics. Alpine is employing directed evolution
to create potentially powerful multifunctional immunotherapies to
improve patients’ lives. Alpine has two lead programs. The first,
ALPN-101 for autoimmune/inflammatory diseases, is a dual ICOS/CD28
antagonist, engineered to reduce pathogenic immune responses. ALPN-101
is currently enrolling a Phase I healthy volunteer trial. The second,
ALPN-202 for cancer, is a dual PD-L1/CTLA-4 antagonist and
PD-L1-dependent CD28 costimulator intended to combine checkpoint
inhibition with T cell costimulation - an approach currently absent from
approved checkpoint therapies. Alpine is backed by world-class research
and development capabilities, a highly-productive scientific platform,
and a proven management team. For more information, visit www.alpineimmunesciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190524005014/en/
Source: Alpine Immune Sciences, Inc.
Investor Relations:
Pure Communications
Courtney Dugan,
212-257-6723
[email protected]
Media Relations:
Pure Communications
Jennifer Paganelli,
347-658-8290
[email protected]
